200例肺部肿瘤SBRT的经验和疗效

doi:10.3760/cma.j.issn.1004-4221.2017.06.004

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (771 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the safety and clinical efficacy of stereotactic body radiation therapy (SBRT) for lung cancer. Methods A retrospective analysis was performed on 200 patients with primary non-small cell lung cancer (NSCLC)(118 patients) or solitary pulmonary metastasis (82 patients) who underwent SBRT in Zhejiang Cancer Hospital from January 2012 to September 2015. The 80% isodose line covered 95% of the planning target volume, and the 100% isodose line covered 100% of the internal gross tumor volume. The fractional dose was 4.0-18.0 Gy daily or every other day, and the biologically equivalent dose ranged from 40.0 to 151.2 Gy (median 100 Gy). Results All patients completed treatment. The follow-up rate was 96.0%. The complete response and partial response rates were 14.8%(17/115) and 65.2%(75/115) for the primary tumor group, versus 25%(19/77) and 38%(29/77) for the metastasis group. The incidence rates of grade Ⅱ and Ⅲ acute radiation pneumonitis were 4.7% and 3.1%, respectively. The median follow-up was 14.9 months. The 1-and 2-year local control rates were 95.7% and 84.3% for the primary tumor group, versus 92% and 73% for the metastasis group. The 1-and 2-year overall survival rates were 94.5% and 92.0% for the primary tumor group, versus 85% and 62% for the metastasis group. Conclusions SBRT is a safe and effective treatment for early primary NSCLC and solitary pulmonary metastasis, resulting in high 1-and 2-year local control and overall survival rates and low rate of complications.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Dong Baiqiang
	Xu Yujin
	Sun Xiaojiang
	Zheng Xiao
	Du Xianghui
	Di Xiaoyun
	Shan Guoping
	Chen Weijun
	Li Pu
	Li Jianlong
	Shao Kainan
	Xu Yaping
	Chen Ming

Key words： Lung neoplasms/stereotactic body radiation therapy Isolated pulmonary metastasis/stereotactic body radiation therapy Treatment outcome

Received: 29 September 2016

Corresponding Authors: Chen Ming,Email:chenming@zjcc.org.cn;Xu Yaping,Email:xuyaping1207@163.com

Cite this article:

Dong Baiqiang,Xu Yujin,Sun Xiaojiang et al. Experience and efficacy of SBRT for lung cancer:an analysis of 200 patients[J]. Chinese Journal of Radiation Oncology, 2017, 26(6): 627-630.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.06.004 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I6/627

[1] 郭梅花,林琳,乔丽.三维适形放疗同期NP方案化疗治疗局部晚期非小细胞肺癌临床观察[J].中华临床医师杂志(电子版),2012,6(4):1040-1041.DOI:10.3877/cma.j.issn.1674-0785.2012.04.060.
Guo MH,Lin L,Qiao L.Clinical observation of three dimensional conformal radiotherapy combined with NP regimen chemotherapy for locally advanced non small cell lung cancer[J].Chin J Clinicians (elect ver),2012,6(4):1040-1041.DOI:10.3877/cma.j.issn.1674-0785.2012.04.060.
[2] Jeppesen SS,Schytte T,Jensen HR,et al. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer:an updated retrospective study on local failure and survival rates[J].Acta Oncol,2013,52(7):1552-1558.DOI:10.3109/0284186X.2013.813635.
[3] Shen YL,Zhang H,Wang J,et al. Hypofractionated radiotherapy for lung tumors with online cone beam CT guidance and active breathing control[J].Radiat Oncol,2010,5(1):19.DOI:10.1186/1748-717X-5-19.
[4] Bradley J.A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group[J].Semin Oncol,2005,32(2 Suppl 3):S111-S113.DOI:10.1053/j.seminoncol.2005.03.020.
[5] Timmerman R,Paulus R,Galvin J,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J].JAMA,2010,303(11):1070-1076.DOI:10.1001/jama.2010.261.
[6] Nagata Y,Hiraoka K,Shibata K,et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T₁N₀M₀ non-small cell lung cancer:Japan clinical oncology group study JCOG0403[J].Int J Radiat Oncol Biol Phys,2015,93(5):989-996.DOI:10.1016/j.ijrobp.2015.07.2278.
[7] Timmerman RD,Paulus R,Pass HI,et al. RTOG 0618:stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients[J].J Clin Oncol,2013,31(15 Suppl):7523.
[8] Chang JY,Senan S,Paul MA,et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-637.DOI:10.1016/S1470-2045(15)70168-3.
[9] Parikh RB,Cronin AM,Kozono DE,et al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2014,89(4):880-887.DOI:10.1016/j.ijrobp.2014.04.007.
[10] Baschnagel AM,Mangona VS,Robertson JM,et al. Lung metastases treated with image-guided stereotactic body radiation therapy[J].Clin Oncol,2013,25(4):236-241.DOI:10.1016/j.clon.2012.12.005.
[11] Onishi H,Araki T,Shirato H,et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multiinstitutional study[J].Cancer,2004,101(7):1623-1631.DOI:10.1002/cncr.20539.
[12] 夏廷毅,孙庆选,李平,等.体部γ-刀高分次剂量治疗Ⅰ—Ⅱ期非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2005,10(1):20-24.DOI:10.3969/j.issn.1009-0460.2005.01.00.
Xia TY,Sun QX,Li P,et al. Clinical study of body gamma knife in the treatment of non-small cell lung cancer:preliminary results of a pilot study[J].Chin Clin Oncol,2005,10(1):20-24.DOI:10.3969/j.issn.1009-0460.2005.01.00.